Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Receives Average Rating of “Buy” from Brokerages

Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) have earned a consensus recommendation of “Buy” from the five research firms that are covering the firm, MarketBeat.com reports. Five equities research analysts have rated the stock with a buy recommendation. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $36.60.

Several analysts recently issued reports on the stock. Evercore ISI upped their price target on shares of Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the company an “outperform” rating in a report on Wednesday, October 30th. JPMorgan Chase & Co. upped their target price on shares of Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the company an “overweight” rating in a research note on Tuesday, November 5th. Finally, Jefferies Financial Group assumed coverage on Kiniksa Pharmaceuticals in a research note on Friday, September 13th. They issued a “buy” rating and a $40.00 price target for the company.

Insider Activity

In other Kiniksa Pharmaceuticals news, COO Eben Tessari sold 17,500 shares of the stock in a transaction on Monday, September 23rd. The stock was sold at an average price of $24.99, for a total value of $437,325.00. Following the sale, the chief operating officer now directly owns 116,975 shares of the company’s stock, valued at $2,923,205.25. This trade represents a 13.01 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Mark Ragosa sold 8,969 shares of the business’s stock in a transaction on Tuesday, December 3rd. The shares were sold at an average price of $21.45, for a total transaction of $192,385.05. Following the transaction, the chief financial officer now directly owns 22,958 shares of the company’s stock, valued at approximately $492,449.10. This trade represents a 28.09 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 44,592 shares of company stock valued at $1,110,364. Company insiders own 54.57% of the company’s stock.

Institutional Trading of Kiniksa Pharmaceuticals

Several hedge funds have recently bought and sold shares of the company. Quarry LP acquired a new stake in shares of Kiniksa Pharmaceuticals in the third quarter valued at approximately $50,000. CWM LLC increased its position in Kiniksa Pharmaceuticals by 443.0% in the 3rd quarter. CWM LLC now owns 2,449 shares of the company’s stock valued at $61,000 after acquiring an additional 1,998 shares during the period. nVerses Capital LLC acquired a new position in Kiniksa Pharmaceuticals during the 3rd quarter worth $80,000. Ashton Thomas Private Wealth LLC bought a new position in shares of Kiniksa Pharmaceuticals in the second quarter worth $100,000. Finally, Lynx1 Capital Management LP acquired a new position in shares of Kiniksa Pharmaceuticals during the second quarter valued at $177,000. 53.95% of the stock is currently owned by institutional investors.

Kiniksa Pharmaceuticals Price Performance

Shares of Kiniksa Pharmaceuticals stock opened at $20.59 on Friday. Kiniksa Pharmaceuticals has a 1-year low of $16.56 and a 1-year high of $28.15. The company has a market capitalization of $1.49 billion, a PE ratio of -147.06 and a beta of 0.27. The business has a 50-day moving average of $22.79 and a 200-day moving average of $23.09.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last posted its quarterly earnings data on Tuesday, October 29th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.17). Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The business had revenue of $112.21 million for the quarter, compared to analysts’ expectations of $111.51 million. During the same quarter in the prior year, the firm earned ($0.20) earnings per share. Kiniksa Pharmaceuticals’s revenue for the quarter was up 67.4% compared to the same quarter last year. On average, equities analysts expect that Kiniksa Pharmaceuticals will post -0.55 earnings per share for the current fiscal year.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.